Edgewise Therapeutics (EWTX) Earnings Date & Reports

Key Takeaways

• Edgewise reported third-quarter 2026 net income of $1.166 billion, or $9.65 per diluted share, swinging from a net loss of $40.7 million a year earlier.
• The turnaround was driven by a one-time $1.348 billion gain from the completed sale of its sevasemten program and muscular dystrophy business to Servier.
• Beneath the headline, the company remains unprofitable, posting a loss from operations of $46.1 million, roughly flat versus $46.9 million in the prior-year quarter.
• Cash, cash equivalents and marketable securities climbed to approximately $1.74 billion, sharply higher than $530.1 million at the end of 2025.
• Edgewise is now a cardiovascular-focused biotech, with a Phase 3 trial of its lead candidate EDG-7500 expected to begin by the end of 2026.
• For more detail on the ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages on Tickeron.
• Explore Trending AI Robots to discover automated strategies and trading ideas across the market.

Earnings Context and Why It Matters

This quarter represents a genuine inflection point for Edgewise Therapeutics. In July 2026, the company completed the sale of sevasemten and its muscular dystrophy business to Servier, receiving roughly $1.396 billion in upfront cash. The transaction fundamentally recasts the business: a cash-consuming, clinical-stage developer is now a well-capitalized, cardiovascular-focused company. Investors are watching how this one-time gain contrasts with Edgewise's ongoing operating losses and whether a fortified balance sheet meaningfully de-risks its two lead programs, EDG-7500 and EDG-15400. For a company with no product revenue, the ability to self-fund pivotal trials without dilutive financing is a central theme of this report.

Reported Results

Edgewise Therapeutics reported third-quarter 2026 net income of $1,166.2 million, or $10.71 per basic share and $9.65 per diluted share, compared with a net loss of $40.7 million, or $0.39 per share, in the third quarter of 2025. The result was almost entirely attributable to a $1.348 billion gain recognized on the sale of the sevasemten program and muscular dystrophy business to Servier, partially offset by $155.3 million in income tax expense tied to the transaction.

Excluding that gain, the underlying business remains unprofitable. Loss from operations was $46.1 million, little changed from $46.9 million a year earlier. Research and development (R&D) expenses declined to $31.6 million from $37.5 million, reflecting lower sevasemten-related costs following the sale, partially offset by higher spending on EDG-7500. General and administrative (G&A) expenses rose to $14.6 million from $9.4 million on higher personnel and professional costs.

As a clinical-stage company, Edgewise generated no product revenue during the quarter. Cash, cash equivalents and marketable securities totaled approximately $1,743.9 million as of September 30, 2026, up from $530.1 million at year-end 2025.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking earnings-driven movers like Edgewise Therapeutics, it offers a structured way to narrow the universe and focus on actionable setups.

Market Reaction and Investor Sentiment

Edgewise shares surged 17.9% to an all-time high when the Servier transaction was first announced in June 2026, and the stock has delivered a strong year-to-date advance. The third-quarter report itself carried little incremental surprise, since the gain had been telegraphed well before the filing. As a result, investor attention has shifted from the one-time windfall to execution of the cardiovascular pipeline. Notably, short interest remains elevated at roughly 10% to 11% of shares outstanding, suggesting a meaningful portion of the market is betting against the stock, while the consensus analyst price target sits well above the current share price. This mix of strong momentum and persistent skepticism underscores how much now hinges on upcoming clinical milestones rather than the quarter's accounting gain.

Forward Outlook and Key Factors to Monitor

The single most important near-term catalyst is the initiation of a Phase 3 trial for EDG-7500, Edgewise's oral cardiac sarcomere modulator being developed for hypertrophic cardiomyopathy (HCM), a condition in which the heart muscle thickens abnormally. Management has guided for the Phase 3 study to start by the end of 2026, following positive 12-week data from the Phase 2 CIRRUS-HCM program.

In parallel, investors should track enrollment in the Phase 2 EQUINOX-HFpEF trial of EDG-15400, a selective cardiac sarcomere modulator targeting heart failure with preserved ejection fraction (HFpEF), a form of heart failure where the heart pumps normally but struggles to relax and fill with blood. Edgewise dosed its first patient in that study during the third quarter.

Financially, the company has signaled that operating losses will continue and that R&D spending is expected to rise substantially as later-stage trials expand. The approximately $1.74 billion cash position provides considerable runway, with management indicating the funds cover planned spending well beyond the next twelve months and are expected to fully support EDG-7500 development through a potential approval. Additional upside could come from up to $1.1 billion in regulatory and commercial milestone payments from Servier, though those remain contingent on future development and commercialization outcomes.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations